Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL339345 | 1.00 | — | — | |
| SCHEMBL329286 | 0.97 | — | — | |
| SCHEMBL29561298 | 0.97 | — | — | |
| Water SCHEMBL31387974 | 0.94 | — | — | |
| Bromide SCHEMBL636756 | 0.94 | — | — | |
| Iodide SCHEMBL29514693 | 0.94 | — | — | |
| Water SCHEMBL9746989 | 0.94 | — | — | |
| Fluoride Ion SCHEMBL12474461 | 0.94 | — | — | |
| Iodide SCHEMBL1807663 | 0.94 | — | — | |
| SCHEMBL28583506 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622978-A1 | PROCESS FOR THE PRODUCTION OF HYDRIDOSILANES | Momentive Performance Materials GmbH (DE) | 2025-10-01 | — | — | EP | disclosed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024110270-A1 | PROCESS FOR THE PRODUCTION OF HYDRIDOSILANES | MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) | 2024-05-30 | — | — | WO | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11497726-B2 | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes | DFB SORIA, LL. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220331261-A1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA, LLC | 2022-10-20 | — | — | US | disclosed |
| US-11331278-B2 | Delivery of drug nanoparticles and methods of use thereof | DFB SORIA, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220117882-A1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220047513-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2022-02-17 | — | — | US | disclosed |